by Dr. Ed Weber | Nov 20, 2023 | PCa Commentary
A forceful sea change is roiling in the management of this disease: artificial intelligence (AI) is coming into prominence benefiting cancer diagnosis, risk stratification and the prediction of response to therapy for individual patients. Multimodal AI (using deep...
by Dr. Ed Weber | Oct 11, 2023 | PCa Commentary
With the increased use of PSMA PET/CT scanning both at initial diagnosis of advanced prostate cancer and at disease recurrence, a substantial number of men will be found to have some extent of metastatic disease — either metastatic hormone sensitive prostate cancer...
by Dr. Ed Weber | Sep 28, 2023 | PCa Commentary
Background: The function of initial staging of prostate cancer is to accurately estimate the risk of progression in order to guide optimal therapy. The influential National Comprehensive Cancer Network (NCCN) recommends a PSMA PET/CT as part of initial staging for...
by Dr. Ed Weber | Aug 4, 2023 | PCa Commentary
Background: Ever since 1675 when the Dutch lens maker, Leeuwenhoek, looked down the newly invented microscope at rainwater and reported seeing ‘animalcules – tiny dancing creatures” (bacteria), pathologists have been similarly looking down their scopes and guiding...
by Dr. Ed Weber | Aug 4, 2023 | PCa Commentary
Background: Although neuroendocrine cancer (NEPC) infrequently (<2%) presents elusively in the prostate, much more commonly it develops late in the course of disease admixed in varying extent in metastatic lesions with standard adenocarcinoma. In this situation...
by Dr. Ed Weber | Jun 19, 2023 | PCa Commentary
The outcome of the VISION trial, the first reported study of radioligand therapy (RLT) with the radionuclide 177-Lutetium-PSMA-617 targeting the PSMA antigen now serves as the baseline for further development of this promising treatment. The VISION trial studied 831...
